These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 24797866)

  • 1. [Endothelin: From discovery to pharmacotherapeutic innovations].
    Richard V
    Presse Med; 2014; 43(7-8):742-55. PubMed ID: 24797866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macitentan for the treatment of pulmonary arterial hypertension.
    DuBrock HM; Channick RN
    Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction.
    Holm P
    Scand Cardiovasc J Suppl; 1997; 46():1-40. PubMed ID: 9265559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of macitentan for the treatment of pulmonary arterial hypertension.
    Selej M; Romero AJ; Channick RN; Clozel M
    Ann N Y Acad Sci; 2015 Nov; 1358():68-81. PubMed ID: 26291180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension].
    Avdeev SN
    Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
    Belge C; Delcroix M
    Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
    Sidharta PN; Krähenbühl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension.
    Steriade A; Seferian A; Jaïs X; Savale L; Jutant EM; Parent F; Sitbon O; Humbert M; Simonneau G; Montani D
    Ther Adv Respir Dis; 2014 Jun; 8(3):84-92. PubMed ID: 24728960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors.
    Iglarz M; Steiner P; Wanner D; Rey M; Hess P; Clozel M
    J Cardiovasc Pharmacol; 2015 Oct; 66(4):332-7. PubMed ID: 25992919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Dingemanse J; Sidharta PN; Maddrey WC; Rubin LJ; Mickail H
    Expert Opin Drug Saf; 2014 Mar; 13(3):391-405. PubMed ID: 24261583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension.
    Clozel M
    Am J Physiol Regul Integr Comp Physiol; 2016 Oct; 311(4):R721-R726. PubMed ID: 27534881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macitentan: A Review in Pulmonary Arterial Hypertension.
    Keating GM
    Am J Cardiovasc Drugs; 2016 Dec; 16(6):453-460. PubMed ID: 27580996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macitentan for the treatment of pulmonary arterial hypertension.
    Hong IS; Coe HV; Catanzaro LM
    Ann Pharmacother; 2014 Apr; 48(4):538-47. PubMed ID: 24458948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension.
    Clarke M; Walter C; Agarwal R; Kanwar M; Benza RL
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):415-21. PubMed ID: 24851934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?
    Jacobs A; Preston IR; Gomberg-Maitland M
    Curr Med Res Opin; 2006 Dec; 22(12):2567-74. PubMed ID: 17166339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Role of Endothelin in Early Vascular Aging.
    Trindade M; Oigman W; Fritsch Neves M
    Curr Hypertens Rev; 2017; 13(1):33-40. PubMed ID: 28413991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders.
    Spieker LE; Noll G; Lüscher TF
    Am J Cardiovasc Drugs; 2001; 1(4):293-303. PubMed ID: 14728028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Abman SH
    Annu Rev Med; 2009; 60():13-23. PubMed ID: 18764741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macitentan and morbidity and mortality in pulmonary arterial hypertension.
    Pulido T; Adzerikho I; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Jing ZC; Le Brun FO; Mehta S; Mittelholzer CM; Perchenet L; Sastry BK; Sitbon O; Souza R; Torbicki A; Zeng X; Rubin LJ; Simonneau G;
    N Engl J Med; 2013 Aug; 369(9):809-18. PubMed ID: 23984728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis.
    Raja SG
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1066-73. PubMed ID: 20730702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.